DOI resolved by resea
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial on resea.org. DOI 10.1016/s0140-6736(1…
Masatoshi Kudo, Richard S. Finn, Shukui Qin, Kwang‐Hyub Han, Kenji Ikeda, Fabio Piscaglia, Ari David Baron, Joong‐Won Park
https://resea.org/10.1016/s0140-6736(18)30207-1